Investment in Britain’s key life sciences sector is at risk as the commercial environment has gone “backwards” and become “unsustainable”, a senior executive at Johnson & Johnson has warned.
Kris Sterkens, chairman of innovative medicines for the US pharma giant in Europe, the Middle East and Africa, said it had invested less in UK research and development in the past ten years, compared with the prior decade, “at the benefit of other countries” who provide better market access to new medicines.
“From a commercial point of view the UK has become a very difficult market to recognise innovation. In fact, it’s a market compared with other major markets in Europe that seems to be going backwards,” he added.
Sterkens’s intervention comes amid fierce lobbying by
